KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00. The downgrade reflects a shift in the investment firm's perspective on the ...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

EQS-Adhoc: Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition ...

BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

JOHNSON CITY, Tenn., Feb. 3, 2025 /PRNewswire/ -- LabConnect, a leading provider of central lab services and functional ...

They include U.S. government securities, municipals, mortgage and asset-backed, foreign bonds, and corporate bonds. In a well-diversified investment portfolio, highly-rated corporate bonds with ...

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed. By Christina Jewett and Sheryl Gay Stolberg ...